Genome-Wide Analysis of Glioblastoma Patients with Unexpectedly Long Survival.

Glioblastoma (GBM), representing WHO grade IV astrocytoma, is a relatively common primary brain tumor in adults with an exceptionally dismal prognosis. With an incidence rate of over 10 000 cases in the United States annually, the median survival rate ranges from 10-15 months in IDH1/2-wildtype tumors and 24-31 months in IDH1/2-mutant tumors, with further variation depending on factors such as age, MGMT methylation status, and treatment regimen. We present a cohort of 4 patients, aged 37-60 at initial diagnosis, with IDH1-mutant GBMs that were associated with unusually long survival intervals after the initial diagnosis, currently ranging from 90 to 154 months (all still alive). We applied genome-wide profiling with a methylation array (Illumina EPIC Array 850k) and a next-generation sequencing panel to screen for genetic and epigenetic alterations in these tumors. All 4 tumors demonstrated methylation patterns and genomic alterations consistent with GBM. Three out of four cases showed focal amplification of the CCND2 gene or gain of the region on 12p that included CCND2, suggesting that this may be a favorable prognostic factor in GBM. As this study has a limited sample size, further evaluation of patients with similar favorable outcome is warranted to validate these findings.

[1]  M. Snuderl,et al.  Genetic and Epigenetic Features of Rapidly Progressing IDH-Mutant Astrocytomas , 2018, Journal of neuropathology and experimental neurology.

[2]  Till Acker,et al.  DNA methylation-based classification of central nervous system tumours , 2018, Nature.

[3]  Xiaoqi Zheng,et al.  InfiniumPurify: An R package for estimating and accounting for tumor purity in cancer methylation research , 2018, Genes & diseases.

[4]  Hideo Nakamura,et al.  Prognostic relevance of genetic alterations in diffuse lower-grade gliomas , 2018, Neuro-oncology.

[5]  Y. Marie,et al.  Same-day genomic and epigenomic diagnosis of brain tumors using real-time nanopore sequencing , 2017, Acta Neuropathologica.

[6]  David T. W. Jones,et al.  Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery , 2017, Acta neuropathologica communications.

[7]  E. Maher,et al.  Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis , 2017, Journal of Neuro-Oncology.

[8]  Shaofeng Yan,et al.  Highly expressed lncRNA CCND2-AS1 promotes glioma cell proliferation through Wnt/β-catenin signaling. , 2017, Biochemical and biophysical research communications.

[9]  F. Forti,et al.  A Cyclin D2-derived peptide acts on specific cell cycle phases by activating ERK1/2 to cause the death of breast cancer cells. , 2017, Journal of proteomics.

[10]  Selene M. Virk,et al.  Integrated genomic analysis of survival outliers in glioblastoma , 2016, Neuro-oncology.

[11]  Hao Wu,et al.  Estimating and accounting for tumor purity in the analysis of DNA methylation data from cancer studies , 2017, Genome Biology.

[12]  David T. W. Jones,et al.  Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): an epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway , 2016, Acta Neuropathologica.

[13]  David T. W. Jones,et al.  Gain of 12p encompassing CCND2 is associated with gemistocytic histology in IDH mutant astrocytomas , 2016, Acta Neuropathologica.

[14]  M. Rosenblum,et al.  Long-term survival in a patient with glioblastoma on antipsychotic therapy for schizophrenia: a case report and literature review , 2016, Therapeutic advances in medical oncology.

[15]  J. Golfinos,et al.  Pilocytic astrocytoma and glioneuronal tumor with histone H3 K27M mutation , 2016, Acta Neuropathologica Communications.

[16]  Jason B. Nikas.  Independent validation of a mathematical genomic model for survival of glioma patients. , 2016, American journal of cancer research.

[17]  D. Compton,et al.  Chromosomal Instability Affects the Tumorigenicity of Glioblastoma Tumor-Initiating Cells. , 2016, Cancer discovery.

[18]  M. Cowperthwaite,et al.  Molecular Predictors of Long-Term Survival in Glioblastoma Multiforme Patients , 2016, PloS one.

[19]  Nour-al-dain Marzouka,et al.  CopyNumber450kCancer: baseline correction for accurate copy number calling from the 450k methylation array , 2015, Bioinform..

[20]  S. South,et al.  DNA copy number analysis of Grade II–III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status , 2015, Acta neuropathologica communications.

[21]  Gabriele Schackert,et al.  Molecular characterization of long‐term survivors of glioblastoma using genome‐ and transcriptome‐wide profiling , 2014, International journal of cancer.

[22]  C. Brennan,et al.  Transcriptional diversity of long-term glioblastoma survivors. , 2014, Neuro-oncology.

[23]  Martin Sill,et al.  Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. , 2014, Neuro-oncology.

[24]  Martin Sill,et al.  Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma , 2014, Acta Neuropathologica.

[25]  J. Barnholtz-Sloan,et al.  The epidemiology of glioma in adults: a "state of the science" review. , 2014, Neuro-oncology.

[26]  F. Gozzo,et al.  A Novel Intracellular Peptide Derived from G1/S Cyclin D2 Induces Cell Death* , 2014, The Journal of Biological Chemistry.

[27]  Thomas Welzel,et al.  A comparison of long-term survivors and short-term survivors with glioblastoma, subventricular zone involvement: a predictive factor for survival? , 2014, Radiation oncology.

[28]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[29]  D. Haussler,et al.  The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.

[30]  H Aburatani,et al.  The critical role of cyclin D2 in cell cycle progression and tumorigenicity of glioblastoma stem cells , 2013, Oncogene.

[31]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[32]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. , 2013, Neuro-oncology.

[33]  David T. W. Jones,et al.  Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. , 2012, Cancer cell.

[34]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[35]  A. McKenna,et al.  Absolute quantification of somatic DNA alterations in human cancer , 2012, Nature Biotechnology.

[36]  J. King,et al.  Adult glioblastoma multiforme survival in the temozolomide era: A population‐based analysis of Surveillance, Epidemiology, and End Results registries , 2012, Cancer.

[37]  C. Kruchko,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. , 2012, Neuro-oncology.

[38]  R. Dubrow,et al.  Demographic variation in incidence of adult glioma by subtype, United States, 1992-2007 , 2011, BMC Cancer.

[39]  G. Reifenberger,et al.  Differential retinoic acid signaling in tumors of long- and short-term glioblastoma survivors. , 2011, Journal of the National Cancer Institute.

[40]  R. McLendon,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[41]  P. Kleihues,et al.  IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas , 2009, Clinical Cancer Research.

[42]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[43]  C. Conti,et al.  Cyclin D2 and cyclin D3 play opposite roles in mouse skin carcinogenesis , 2007, Oncogene.

[44]  Thomas Lengauer,et al.  Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment. , 2005, Neoplasia.

[45]  K. Ichimura,et al.  Mutations in Rb1 pathway-related genes are associated with poor prognosis in Anaplastic Astrocytomas , 2005, British Journal of Cancer.

[46]  F. McCormick,et al.  The RB and p53 pathways in cancer. , 2002, Cancer cell.

[47]  S. Weitzman,et al.  Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. , 2001, Cancer research.

[48]  A. Friedman,et al.  Comparative genetic patterns of glioblastoma multiforme: potential diagnostic tool for tumor classification. , 2000, Neuro-oncology.

[49]  Y. Yonekawa,et al.  Loss of Heterozygosity on Chromosome 19 in Secondary Glioblastomas , 2000, Journal of neuropathology and experimental neurology.

[50]  Stefano Colella,et al.  Loss of Heterozygosity on Chromosome 10 Is More Extensive in Primary (De Novo) Than in Secondary Glioblastomas , 2000, Laboratory Investigation.

[51]  R. Sutherland,et al.  Cyclin D2 activates Cdk2 in preference to Cdk4 in human breast epithelial cells , 1997, Oncogene.